Sub-dissociative Intranasal Ketamine for Pediatric Sickle Cell Pain Crises
Status:
Unknown status
Trial end date:
2019-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if the use of ketamine, sniffed in the nose, is a
safe and effective way to help reduce pain in pediatric sickle cell patients with pain crises
in resource-limited settings.
Phase:
N/A
Details
Lead Sponsor:
Cameroon Baptist Convention Health
Collaborators:
Carolinas Medical Center Muhimbili National Hospital